{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:32:55Z","timestamp":1772613175981,"version":"3.50.1"},"reference-count":28,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2283,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1111\/j.1399-5448.2008.00490.x","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T18:29:07Z","timestamp":1229711347000},"page":"264-268","source":"Crossref","is-referenced-by-count":19,"title":["Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus"],"prefix":"10.1155","volume":"10","author":[{"given":"Krishnavathana","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubina A","family":"Heptulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1399-543X.2006.00159.x","article-title":"Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations","volume":"7","author":"Jeha","year":"2006","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1345\/aph.1C387","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB3","doi-asserted-by":"crossref","first-page":"4S40","DOI":"10.1016\/S1262-3636(05)88266-7","article-title":"Intensive insulin therapy today: \u2018basal-bolus\u2019 using multiple daily injections or CSII?","volume":"31","author":"Renard","year":"2005","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/BF03346351","article-title":"Basal insulin supplementation in type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin","volume":"30","author":"Schiaffini","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB5","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2337\/diacare.24.11.1858","article-title":"Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes","volume":"24","author":"Boland","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB6","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2337\/diacare.24.12.2030","article-title":"A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects","volume":"24","author":"Kaufman","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1203\/PDR.0b013e318159af8c","article-title":"The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes","volume":"62","author":"Rodriguez","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes","volume":"54","author":"Heptulla","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diabetes.46.4.632","article-title":"Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial","volume":"46","author":"Thompson","year":"1997","journal-title":"Diabetes"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-291X(91)91325-7","article-title":"Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents","volume":"179","author":"Moore","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB12","first-page":"1831","article-title":"Therapies for diabetes: pramlintide and exenatide","volume":"75","author":"Jones","year":"2007","journal-title":"Am Fam Physician"},{"issue":"Suppl. 2","key":"10.1111\/j.1399-5448.2008.00490.x-BIB13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S9::AID-DIA397>3.3.CO;2-4","article-title":"Amylin: history and overview","volume":"14","author":"Ludvik","year":"1997","journal-title":"Diabet Med"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1111\/j.1399-5448.2008.00490.x-BIB15","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S19::AID-DIA400>3.3.CO;2-W","article-title":"Effects of amylin and the amylin agonist pramlintide on glucose metabolism","volume":"14","author":"Schmitz","year":"1997","journal-title":"Diabet Med"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(05)52008-8","article-title":"Inhibition of glucagon secretion","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB17","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.2000.278.6.G946","article-title":"Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition","volume":"278","author":"Samsom","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clinthera.2007.04.005","article-title":"Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus","volume":"29","author":"Singh-Franco","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB22","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2146\/ajhp050341","article-title":"Pramlintide acetate","volume":"62","author":"McQueen","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/clinchem\/42.4.576","article-title":"Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma","volume":"42","author":"Percy","year":"1996","journal-title":"Clin Chem"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00063030-200317010-00008","article-title":"Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin)","volume":"17","year":"2003","unstructured":"27.\u2002Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin). BioDrugs 2003: 17: 73-79.","journal-title":"BioDrugs"},{"key":"10.1111\/j.1399-5448.2008.00490.x-BIB28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"}],"container-title":["Pediatric Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5448.2008.00490.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1399-5448.2008.00490.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:07:32Z","timestamp":1671818852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5448.2008.00490.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1399-5448.2008.00490.x","relation":{},"ISSN":["1399-543X","1399-5448"],"issn-type":[{"value":"1399-543X","type":"print"},{"value":"1399-5448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}